over 2 years ago • 3 mins
I’m a 40-something investor from the Netherlands focusing on value and dividend stocks. I like to think independently and look for investment opportunities that are not yet popular.
Grifols, a Spanish healthcare firm (ticker: GRF). The company should profit from the world’s aging population and the increasing use of immunotherapies and blood-derived products and medicines. I believe the stock has fallen too much since the coronavirus pandemic began, as investors are overly pessimistic about its impact on plasma collections. After all, worldwide demand for plasma is on the increase. For me, Grifols is a reliable investment with excellent long-term prospects. It operates in an underfollowed industry and in a market with high barriers to entry for new competitors.
Grifols is the world’s largest producer of blood plasma and immunoglobulin, with very few competitors. It operates in four business segments: Bioscience (plasma and plasma-derived medicine), Diagnostics, Hospital, Bio Supplies, and Others. The Bioscience segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital segment comprises all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third- party companies.
Grifols is a dominant market player in an industry set to be a steady grower for many years. This is a classical compounder, with a current dividend yield of around 2.6% (payout ratio around 35%), operating in an industry with high barriers to entry. The stock has been hit during the COVID pandemic due to fears of plasma collection shortfalls. I believe these fears will prove overblown. Being under the radar, the stock still trades around 50% lower than its pre-COVID price, while the market and industry dynamics have not changed.
There are some inherent risks in blood products such as the risk of new and unknown virus infection. Also potential recombinant substitute products are a risk, but so far blood plasma-based products have proven to be superior and more effective.
What do you think of Sam's pitch? Let us know here.
Disclaimer: These articles are provided for information purposes only. Occasionally, an opinion about whether to buy or sell a specific investment may be provided. The content is not intended to be a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy as it is not provided based on an assessment of your investing knowledge and experience, your financial situation or your investment objectives. The value of your investments, and the income derived from them, may go down as well as up. You may not get back all the money that you invest. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment advisor.